The global lysosomal acid lipase deficiency (LAL-D) treatment market size is likely to reach USD 954 million by 2025, as per a new report by Grand View Research, Inc., exhibiting a 10.8% CAGR during the forecast period. High unmet needs, rising prevalence, and increasing uptake of enzyme replacement therapy are some of the primary factors driving the market.
LAL
deficiency (LAL-D) is a rare type of lysosomal storage disorder in which
patients are unable to breakdown cholesteryl esters and triglycerides due to a
mutation in the LAL gene. As a result, there is an accumulation of lipids in
the liver, spleen, and walls of blood vessels. LAL deficiency is a progressive
disease with multi-systemic clinical manifestations, significant medical
complications, and early mortality due to liver failure, especially among
infants.
Until
2015, the global LAL deficiency treatment market witnessed modest growth due to
a lack of approved treatments for the disease. Medical care was limited to
supportive care, with surgery and lipid-modifying drugs such as statins
remained the mainstay for treatment. In 2015, approval of Alexion Pharma’s
Kanuma (sebelipase alfa) marked the entry of enzyme replacement therapy (ERT)
in the LAL-D space. Kanuma is a hydrolytic lysosomal cholesterol ester and
triacylglycerol specific enzyme, administered intravenously in patients with
LAL deficiency. Currently, Kanuma is the only drug approved for both Wolman
disease (WD) and Cholesteryl Ester Storage Disease (CESD) in the key markets.
Based
on treatment, supportive care was the leading revenue contributor in the market
in 2017. However, the ERT segment is expected to register the fastest growth
during the forecast period, supported by continued uptake of Kanuma. Disease
prognosis remains poor, as a majority of patients are either undiagnosed or
misdiagnosed. Thus, there remains a strong need for extensive research to
understand disease biology and develop effective therapeutic options with the
goal to overcome resistance and minimize toxicity.
Full Research Report On Lysosomal Acid Lipase Deficiency Treatment Market Visit Here:
https://www.grandviewresearch.com/industry-analysis/lysosomal-acid-lipase-deficiency-lal-d-treatment-market
Further key
findings from the report suggest:
- CESD
manifests later in life and is more prevalent among Caucasians and
Hispanic populations, affecting approximately 1 in 300,000 individuals
- Germany is at
the forefront of the Europe market and is driven by high disease
prevalence and availability of drugs in the ERT class
- Approval of
Kanuma in ERT class highlight a fundamental shift in treatment approach to
LAL-D deficiency
- The ERT
segment is estimated to be the fastest-growing during the forecast period,
owing to Kanuma’s first-mover advantage as the only long-term treatment in
untapped LAL-D patient population pool
- Statins are
anticipated to lose market share due to rising competition from generics
within the class and increasing uptake of Alexion’s Kanuma
- Rising
eligible patient population and limited therapeutic intervention for LAL
deficiency offer a strong commercial opportunity for players to invest in
developing novel treatments in this market
- Lack of
awareness in disease diagnosis and delayed access to medications due to
poor prognosis may restrain the growth of the market.
Request a Sample Copy of the Report @
https://www.grandviewresearch.com/industry-analysis/lysosomal-acid-lipase-deficiency-lal-d-treatment-market/request/rs1
Grand View Research has
segmented the global lysosomal acid lipase deficiency treatment market based on
indication, treatment, and country:
Lysosomal Acid
Lipase Deficiency Indication Outlook (Revenue, USD Million, 2017 - 2025)
- Wolman Disease (WD)
- Cholesteryl Ester Storage Disease (CESD)
Lysosomal Acid
Lipase Deficiency Treatment Outlook (Revenue, USD Million, 2017 - 2025)
- Enzyme Replacement Therapy (ERT)
- Lipid-Modifying Agents (Statins)
- Surgery
- Stem Cell Transplantation
- Supportive Care
Lysosomal Acid
Lipase Deficiency Country Outlook (Revenue, USD Million, 2017 - 2025)
- The U.S.
- The U.K.
- France
- Germany
- Italy
- Spain
- Japan
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment